Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436237 | 0.77 | ALDH1A1 (0.74) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5435047 | 0.77 | HPGD (0.69) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5427695 | 0.72 | KDM4E (0.65) | ALDH1A1POLBMAPTTDP1GAA | |
| SCHEMBL5426957 | 0.72 | ALDH1A1 (0.62) | ALDH1A1HPGDPOLBTDP1GAA | |
| SCHEMBL5429678 | 0.72 | ALDH1A1 (0.66) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5432040 | 0.71 | ALDH1A1 (0.76) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5430416 | 0.71 | ALDH1A1 (0.67) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5432292 | 0.71 | ALDH1A1 (0.89) | ALDH1A1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5426836 | 0.70 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTTDP1GAA | |
| SCHEMBL5429695 | 0.70 | ALDH1A1 (0.51) | ALDH1A1HPGDPOLBMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | claimed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | claimed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | ALDH1A1 151/4885HPGD 114/4885POLB 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.